Advice

following a full submission:

guselkumab (Tremfya®) is accepted for restricted use within NHSScotland.

Indication under review: Treatment of moderate to severe plaque psoriasis in adults who are candidates for systemic therapy.

SMC restriction: for patients who have failed to respond to conventional systemic therapies (including ciclosporin, methotrexate and phototherapy), are intolerant to, or have a contraindication to these treatments.

In two phase III studies, guselkumab was superior to a TNF inhibitor in improving symptoms of moderate to severe plaque psoriasis in adults who are candidates for systemic therapy.

This SMC advice takes account of the benefits of a Patient Access Scheme (PAS) that improves the cost-effectiveness of guselkumab. This advice is contingent upon the continuing availability of the PAS in NHSScotland or a list price that is equivalent or lower.

Download full details372KB (PDF)

Download

Medicine details

Medicine name:
guselkumab (Tremfya)
SMC ID:
SMC No 1340/18
Indication:
Treatment of moderate to severe plaque psoriasis in adults who are candidates for systemic therapy
Pharmaceutical company
Janssen-Cilag Ltd
BNF chapter
Skin
Submission type
Full submission
Status
Restricted
Date advice published:
11 June 2018